221 related articles for article (PubMed ID: 31792211)
1. LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
Li Q; Liu B; Chao HP; Ji Y; Lu Y; Mehmood R; Jeter C; Chen T; Moore JR; Li W; Liu C; Rycaj K; Tracz A; Kirk J; Calhoun-Davis T; Xiong J; Deng Q; Huang J; Foster BA; Gokhale A; Chen X; Tang DG
Nat Commun; 2019 Dec; 10(1):5494. PubMed ID: 31792211
[TBL] [Abstract][Full Text] [Related]
2. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.
Ji Y; Kumar R; Gokhale A; Chao HP; Rycaj K; Chen X; Li Q; Tang DG
Semin Cancer Biol; 2022 Jul; 82():120-133. PubMed ID: 33476721
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.
Guo H; Wu Y; Nouri M; Spisak S; Russo JW; Sowalsky AG; Pomerantz MM; Wei Z; Korthauer K; Seo JH; Wang L; Arai S; Freedman ML; He HH; Chen S; Balk SP
Nat Commun; 2021 Dec; 12(1):7308. PubMed ID: 34911936
[TBL] [Abstract][Full Text] [Related]
4. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
5. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer.
Lim SC; Geleta B; Maleki S; Richardson DR; Kovačević Ž
J Biol Chem; 2021 Dec; 297(6):101414. PubMed ID: 34785213
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
7. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
8. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Vatapalli R; Sagar V; Rodriguez Y; Zhao JC; Unno K; Pamarthy S; Lysy B; Anker J; Han H; Yoo YA; Truica M; Chalmers ZR; Giles F; Yu J; Chakravarti D; Carneiro B; Abdulkadir SA
Nat Commun; 2020 Aug; 11(1):4153. PubMed ID: 32814769
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
[TBL] [Abstract][Full Text] [Related]
11. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
13. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
14. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
15. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
[TBL] [Abstract][Full Text] [Related]
16. The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.
Siddiqui S; Libertini SJ; Lucas CA; Lombard AP; Baek HB; Nakagawa RM; Nishida KS; Steele TM; Melgoza FU; Borowsky AD; Durbin-Johnson BP; Qi L; Ghosh PM; Mudryj M
Cancer Lett; 2020 Jul; 483():12-21. PubMed ID: 32330514
[TBL] [Abstract][Full Text] [Related]
17. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
[TBL] [Abstract][Full Text] [Related]
18. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.
Krig SR; Frietze S; Simion C; Miller JK; Fry WH; Rafidi H; Kotelawala L; Qi L; Griffith OL; Gray JW; Carraway KL; Sweeney C
Mol Cancer Res; 2011 Oct; 9(10):1406-17. PubMed ID: 21821674
[TBL] [Abstract][Full Text] [Related]
19. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
[TBL] [Abstract][Full Text] [Related]
20. ELF5-Mediated AR Activation Regulates Prostate Cancer Progression.
Li K; Guo Y; Yang X; Zhang Z; Zhang C; Xu Y
Sci Rep; 2017 Mar; 7():42759. PubMed ID: 28287091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
